AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a first-line treatment for breast cancer after camizestrant hit the mark in a ...
Measuring trust isn’t enough. Furthering knowledge about the institutions and norms of science is the best way to build credibility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results